1. |
Wang Q, Luo M, Xiang B, et al. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis. Respir Res, 2020, 21(1): 55.
|
2. |
Ataya A, Brantly M, Riley L. Lymphangioleiomyomatosis (LAM). Am J Respir Crit Care Med, 2018, 198(4): P7-P8.
|
3. |
Ataya A, Riley L, Brantly ML. Serum vascular endothelial growth factor D in cystic lung disease. JAMA, 2019, 321(4): 401-402.
|
4. |
Freitas CSG, Baldi BG, Jardim C, et al. Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. Orphanet J Rare Dis, 2017, 12(1): 74.
|
5. |
Gupta N, Henske EP. Pulmonary manifestations in tuberous sclerosis complex. Am J Med Genet C Semin Med Genet, 2018, 178(3): 326-337.
|
6. |
廖新, 况九龙. 血管内皮生长因子-D 对淋巴管平滑肌瘤病诊治价值的研究进展. 中国呼吸与危重监护杂志, 2019, 18(6): 603-605.
|
7. |
Miller S, Coveney C, Johnson J, et al. The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis. Eur Respir J, 2018, 52(5): 1800951.
|
8. |
Gopalakrishnan V, Yao J, Steagall WK, et al. Use of CT imaging to quantify progression and response to treatment in lymphangioleiomyomatosis. Chest, 2019, 155(5): 962-971.
|
9. |
Li C, Zhang E, Sun Y, et al. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis. PLoS One, 2014, 9(10): e104809.
|
10. |
Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A, 1998, 95(2): 548-553.
|
11. |
Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. an official American Thoracic Society/Japanese Respiratory Society clinical practice guideline. Am J Respir Crit Care Med, 2017, 196(10): 1337-1348.
|
12. |
Nascimento ECTD, Baldi BG, Mariani AW, et al. Immunohistological features related to functional impairment in lymphangioleiomyomatosis. Respir Res, 2018, 19(1): 83.
|
13. |
McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med, 2016, 194(6): 748-761.
|
14. |
Hirose M, Matsumuro A, Arai T, et al. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS One, 2019, 14(2): e0212776.
|
15. |
Amaral AF, de Oliveira MR, Dias OM, et al. Concentration of serum vascular endothelial growth factor (VEGF-D) and its correlation with functional and clinical parameters in patients with lymphangioleiomyomatosis from a brazilian reference center. Lung, 2019, 197(2): 139-146.
|
16. |
Mou Y, Ye L, Wang J, et al. Diagnostic and treatment monitoring potential of serum vascular endothelial growth factor-D in lymphangioleiomyomatosis. Lymphology, 2016, 49(3): 140-149.
|
17. |
Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell, 2017, 168(6): 960-976.
|
18. |
Lamattina AM, Taveira-Dasilva A, Goldberg HJ, et al. Circulating biomarkers from the phase 1 trial of sirolimus and autophagy inhibition for patients with lymphangioleiomyomatosis. Chest, 2018, 154(5): 1070-1082.
|
19. |
Kurosaki T, Otani S, Miyoshi K, et al. Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center. Clin Respir J, 2020, 14(2): 116-123.
|
20. |
Zhan Y, Shen L, Xu W, et al. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study. Orphanet J Rare Dis, 2018, 13(1): 34.
|
21. |
Taveira-DaSilva AM, Jones AM, Julien-Williams P, et al. Long-term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with Lymphangioleiomyomatosis. Chest, 2018, 153(1): 124-132.
|
22. |
Lisowska-Myjak B, Jóźwiak-Kisielewska A, Łukaszkiewicz J, et al. Vitamin D-binding protein as a biomarker to confirm specific clinical diagnoses. Expert Rev Mol Diagn, 2020, 20(1): 49-56.
|
23. |
冯娟, 夏维波. 维生素 D 结合蛋白研究进展. 国际内分泌代谢杂志, 2016, 36(3): 209-213.
|
24. |
Bouillon R, Schuit F, Antonio L, et al. Vitamin D binding protein: a historic overview. Front Endocrinol (Lausanne), 2020, 10: 910.
|
25. |
Chishimba L, Thickett DR, Stockley RA, et al. The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax, 2010, 65(5): 456-462.
|
26. |
Gupta N, Vassallo R, Wikenheiser-Brokamp KA, et al. Diffuse cystic lung disease. Part I. Am J Respir Crit Care Med, 2015, 191(12): 1354-1366.
|
27. |
Henske EP, Jóźwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Primers, 2016, 2: 16035.
|
28. |
Logginidou H, Ao X, Russo I, et al. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest, 2000, 117(1): 25-30.
|
29. |
Li C, Li N, Liu X, et al. Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis. JCI Insight, 2016, 1(19): e86629.
|
30. |
Jeong Y, Swami S, Krishnan AV, et al. Inhibition of mouse breast tumor-initiating cells by calcitriol and dietary vitamin D. Mol Cancer Ther, 2015, 14(8): 1951-1961.
|
31. |
Liu HJ, Henske EP. Vitamin D binding protein: a new biomarker of disease severity in lymphangioleiomyomatosis. Eur Respir J, 2018, 52(5): 1801886.
|
32. |
Nijmeh J, El-Chemaly S, Henske EP. Emerging biomarkers of lymphangioleiomyomatosis. Expert Rev Respir Med, 2018, 12(2): 95-102.
|
33. |
Kim SH, Baek MS, Yoon DS, et al. Vitamin D inhibits expression and activity of matrix metalloproteinase in human lung fibroblasts (HFL-1) cells. Tuberc Respir Dis (Seoul), 2014, 77(2): 73-80.
|
34. |
Kim C, Do KH, Cha J, et al. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study. Eur Radiol, 2020, 30(2): 735-743.
|
35. |
Doubková M, Štefániková M, Čan V, et al. Lymphangioleiomyomatosis. Klin Onkol, 2019, 32(5): 367-374.
|
36. |
Larsen TC, Hasani AM, Rollison SF, et al. Clinical CT underestimation of the percentage volume occupied by cysts in patients with lymphangioleiomyomatosis. Clin Imaging, 2020, 59(2): 119-125.
|
37. |
Yao J, Taveira-DaSilva AM, Colby TV, et al. CT grading of lung disease in lymphangioleiomyomatosis. AJR Am J Roentgenol, 2012, 199(4): 787-793.
|
38. |
Lynn E, O’Callaghan M, Sahadevan A, et al. Emerging approaches to predict prognosis and monitor disease progression in lymphangioleiomyomatosis. Am J Respir Crit Care Med, 2019, 200(11): 1424-1426.
|
39. |
Hu-Wang E, Schuzer JL, Rollison S, et al. Chest CT scan at radiation dose of a posteroanterior and lateral chest radiograph series: a proof of principle in lymphangioleiomyomatosis. Chest, 2019, 155(3): 528-533.
|
40. |
Li C, Liu X, Liu Y, et al. Tuberin regulates prostaglandin receptor-mediated viability, via rheb, in mTORC1-hyperactive cells. Mol Cancer Res, 2017, 15(10): 1318-1330.
|
41. |
Lu Y, Liu X, Zhang E, et al. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells. PLoS One, 2020, 15(2): e0228894.
|
42. |
姚懿雯, 李冬. 前列腺素 E 受体在抑制人肺巨噬细胞炎性反应中的作用. 基础医学与临床, 2019, 39(1): 90-91.
|
43. |
Li C, Lee PS, Sun Y, et al. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014, 211(1): 15-28.
|